PORTFOLIO

Project presentations on the website

Every project supported by Gebert Rüf Stiftung is made accessible with a web presentation that informs about the core data of the project. With this public presentation, the foundation publishes the funding results achieved and contributes to the communication of science to society.

Close

SURI Biotech – Improving people’s health by targeting their microbiome

Editorial

Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.

Cooperation

Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen:

Project data

  • Project no: GRS-030/22 
  • Amount of funding: CHF 150'000 
  • Approved: 28.06.2022 
  • Duration: 10.2022 - 04.2024 
  • Area of activity:  InnoBooster, seit 2018

Project management

Project description

The microbiome represents a new area of science with potential to improve human health. At SURI BioTech we untangle the potential of the gut microbiome using rationally selected bacterial strains with clear targets and high efficacy for the alleviation of bloating and gastrointestinal discomfort. Our proprietary bacterial strains are developed based on our strong scientific understanding on the mechanism of bloating and for preventing hydrogen gas production by intestinal microorganisms – with potential applications in multiple functional gastrointestinal disorders (FGDIs) such as infant colic, lactose intolerance and bloating. BactoKind, our first application, is a food supplement containing a consortium of natural bacterial strains for the alleviation of infant colic.
20% of babies younger than 5 months suffer from infant colic, a functional gastrointestinal disorder characterized by inconsolable crying, over 3 hours a day, 3 times a week, which severely impairs quality of life of the parents, and can also trigger maternal post-partum depression. BactoKind is the first microbial solution for infant colic with a clear mechanism of action and will offer relief to the infant’s pain and improve parents’ well-being.

Status/Results

InnoBooster funds will allow us to obtain a first industrial standard prototype of BactoKind as intended to be marketed, demonstrating that our formulation production is scalable and reproducible, and to determine its shelf-life stability. The finished product prototype will also be used to conduct in vivo safety and toxicology tests in animal models as required by regulatory authorities to approve BactoKind strains as food ingredient for inclusion in infant formula. Concomitantly, Innobooster funds will also allow us to establish commercial partnerships with CMOs and distribution partners to launch BactoKind to the market in 2024.

Links

Persons involved in the project

Dr. sc. Vanesa Rocha Martin, project leader
Veronica Zimmermann, project employee, research assistant
Mathilde Dupin, project employee, commercial development

Last update to this project presentation  30.08.2023